From whole monoclonal antibodies to single domain antibodies: Think small

Methods in Molecular Biology

Volumn 911, Issue , 2012, Pages 3-13

  Teillaud, Jean Luc ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Bispecific antibody; Chimeric antibody; Humanized antibody; Intrabody; Monoclonal antibody; Nanobody; Phage display; Single chain Fv; Single domain antibody

Indexed keywords

ABCIXIMAB; BISPECIFIC ANTIBODY; CELL SURFACE PROTEIN; CERTOLIZUMAB PEGOL; ECULIZUMAB; IMMUNOGLOBULIN G; IODINE 131; MONOCLONAL ANTIBODY; NANOBODY; RANIBIZUMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VIVATUXIN I 131;

ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG SYNTHESIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; NONHUMAN; PASSIVE IMMUNIZATION; PHAGE DISPLAY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

EID: 84934435776     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-968-6_1     Document Type: Article

References (56)

1. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of prede fined specificity. Nature 256:495-497
2. Steinitz M et al (1977) Virus induced B lymphocyte cell lines producing speci fic antibodies. Nature 269:420-422
3. Béliard R et al (2008) An anti-D monoclonal antibody selected for enhanced Fc g RIII engagement clears RhD-positive autologous red cells in human volunteers as ef ficiently as polyclonal anti-D antibodies. Br J Haematol 141:109-119
4. Olsson L, Kaplan HS (1980) Human-human hybridomas producing monoclonal antibodies of prede fined antigenic specificity. Proc Natl Acad Sci USA 77:5429-5431
5. Borrebaeck CA, Möller SA (1986) In vitro immunization. Effect of growth and differentiation factors on antigen-speci fic cell activation and production of monoclonal antibodies to autolo-gous antigens and immunogens. J Immunol 13:3710-3715
6. Banchereau J et al (1989) Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science 251:70-72
7. Traggiai E et al (2004) An ef ficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 8:871-875
8. Traggiai E et al (2004) Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304:104-107
9. Morrison SL et al (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81:6851-6855
10. Queen C et al (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 86:10029-10035
11. Chen Y et al (1999) Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 293:865-881
12. Roguska MA et al (1994) Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci USA 91:969-973
13. Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315-1317
14. McCafferty J et al (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552-554
15. Hawkins RE, Russell SJ, Winter G (1992) Selection of phage antibodies by binding affinity: mimicking affinity maturation. J Mol Biol 226:889-896
16. Huse WD et al (1989) Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246: 1275-1281
17. Feldhaus MJ et al (2003) Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol 21:163-170
18. Hanes J et al (2000) Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat Biotechnol 18:1287-1292
19. Lonberg N et al (1994) Antigen-speci fic human antibodies from mice comprising four distinct genetic modi fications. Nature 368:856-859
20. Green LL et al (1994) Antigen-speci fic human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 7:13-21
21. Tomizuka K et al (2000) Double trans-chromo-somic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies. Proc Natl Acad Sci USA 97:722-727
22. Porter RR (1958) Separation and isolation of fractions of rabbit gamma-globulin containing the antibody and antigenic combining sites. Nature 182:670-671
23. Porter RR (1959) The hydrolysis of rabbit gamma-globulin and antibodies with crystalline papain. Biochem J 73:119-26
24. Poljak RJ et al (1973) Three-dimensional structure of the Fab' fragment of a human immuno-globulin at 2.8 A resolution. Proc Natl Acad Sci USA 70:3305-3310
25. Debré M et al (1993) Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342:945-949
26. Anthony RM et al (2008) Recapitulation of IVIG anti-in flammatory activity with a recom-binant IgG Fc. Science 320:373-376
27. Brennan M (1985) Preparation of bispeci fic antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229:81-83
28. Weiner LM et al (1993) A human tumor xeno-graft of therapy with a bispeci fic monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res 53:94-100
29. Michon J et al (1995) In vitro killing of neuro-blastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-Fc gamma RI bispecific antibody. Blood 86:1124-1130
30. Inbar D et al (1972) Localization of antibody-combining sites within the variable portions of heavy and light chains. Proc Natl Acad Sci USA 69:2659-2662
31. Skerra A, Plückthun A (1988) Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240:1038-1041
32. Huston JS et al (1988) Protein engineering of antibody binding sites: recovery of speci fic activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 85:5879-5883
33. Bird RE et al (1988) Single-chain antigen-binding proteins. Science 242:423-426
34. Holliger P et al (1993) "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90:6444-6448
35. Huston JS et al (1991) Protein engineering of single-chain Fv analogs and fusion proteins. Methods Enzymol 203:46-88
36. Kontermann RE, Muller R (1999) Intracellular and cell surface displayed single-chain diabod-ies. J Immunol Methods 226:179-188
37. Bargou R et al (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321:974-977
38. Marasco WA (1997) Intrabodies: turning the humoral immune system outside in for intracel-lular immunization. Gene Ther 4:11-15
39. Marasco WA, Haseltine WA, Chen S (1993) Design, intracellular expression, and activity of a human anti-human immunode ficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci USA 90:7889-7893
40. ras promotes tumor regression. Cancer Res 58: 1170-1176
41. Richardson JH et al (1995) Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha sub-unit of the receptor. Proc Natl Acad Sci USA 92:3137-3141
42. Caron de Fromentel C et al (1999) Restoration of transcriptional activity of p53 mutants in human tumor cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene 18:551-557
43. Nizak C et al (2003) Recombinant antibodies to the small GTPase Rab6 as conformation sensors. Science 300:984-987
44. Cardinale A, Filesi I, Biocca S (2001) Aggresome formation by anti-Ras intracellular scFv fragments. The fate of the antigen-antibody complex. Eur J Biochem 268:268-277
45. Visintin M et al (1999) Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc Nat Acad Sci USA 9:11723-11728
46. Visintin M et al (2002) The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol 317:73-83
47. Proba K et al (1998) Antibody scFv fragments without disul fide bonds made by molecular evolution. J Mol Biol 275:245-253
48. Wirtz P, Steipe B (1999) Intrabody construction and expression III: engineering hyperstable V(H) domains. Protein Sci 8:2245-2250
49. Ross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86:10024-10028
50. Pinthus JH et al (2004) Adoptive immuno-therapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest 114:1774-1781
51. Gruel N, Fridman WH, Teillaud JL (2001) By-passing tumor-speci fic and bispecific antibodies: triggering of antitumor immunity by expression of anti-Fc g R scFv on cancer cell surface. Gene Ther 8:1721-1728
52. Kalergis AM, Ravetch JV (2002) Inducing tumor immunity through the selective engagement of activating Fc g receptors on dendritic cells. J Exp Med 195:1653-1659
53. Ward ES et al (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341:544-546
54. Hamers-Casterman C et al (1993) Naturally occurring antibodies devoid of light chains. Nature 363:446-448
55. Behar G et al (2008) Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel 21:1-10
56. Els Conrath K et al (2001) Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 276:7346-7350